NFATC3 and cardiac hypertrophy: Regarding the cardiac issue, recent studies have demonstrated that TFAM inhibits the NFAT4-MMP9 proteolytic pathway in TFAM transgenic mice subjected to aorticbanding-induced heart failure, reducing pathological cardiac remodeling like hypertrophy and other HF associated factors.